Given that most immunostimulatory nucleic acids are generated through a reverse transcription step in the life cycle of endogenous retroelements, using reverse transcriptase inhibitors, previously utilized in HIV treatment, to limit the production of endogenous nucleic acids that drive aberrant IFN production has shown promise for patients with AGS (Rice et al., 2018). Here, IFNA1 is linked to Aicardi-Goutieres syndrome.